Trial Profile
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs AMP 514 (Primary) ; Durvalumab (Primary) ; Nivolumab
- Indications Bladder cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; MedImmune
- 04 May 2022 Results (n=63) evaluating antitumor activity and safety of MEDI0680 plus durvalumab versus nivolumab monotherapy in immunotherapy naive patients with advanced clear cell renal cell carcinoma, published in the Clinical Cancer Research
- 08 Nov 2020 This trial has been Discontinued in Netherlands, according to European Clinical Trials Database record.
- 10 Apr 2020 Status changed from active, no longer recruiting to completed.